Table 1. Efficacy of PDT for different types of cancer.
| Cancer | Photosensitizer | Response | Cure rate | Publication |
|---|---|---|---|---|
| Photofrin |
96.6% (127/131) |
96.6% |
Muroya21 |
|
| 42% (3/7) | 42% (3/7) | Hillemanns 23 | ||
| 51% (16/31) | 31% (10/31) | Keefe24 | ||
| CIN | 5-ALA | 75% (9/12) | 33% (4/12) | Barnett25 |
| 95% (19/20) | Wierrani 26 | |||
| 91% (10/11) | Borner27 | |||
| |
80% (4/5) |
80% |
Wang29 |
|
| |
HAL |
63% (15/24) |
63% |
Soergel33 |
| 89% | 10% (1/10) | Martin-Hirsh40 | ||
| 5-ALA | 83% | 16% (1/6) | Kurwa41 | |
| VIN | |
64% |
52% (13/25) |
Hillemanns42 |
| |
mTHPC |
|
66% (4/6) |
Cambell44 |
| Ovarian |
Photofrin |
|
15% (2/13) |
Wilson56 |
| Photofrin II | 64% (24/37) | 13.5% (15/37) | Khan77 | |
| Chest wall breast cancer recurrences | Photofrin | 100% (14/14) | 64% (9/14) | Cuenca76 |
| mTHPC | 100% (7/7) | Wyss78 | ||
| Npe6 | 75% (3/4) | 50% (2/4) | Taber75 |
Response means complete ablation or decrease of lesion site. Cure rate means no recurrence of the disease was noted at follow up of 6 months or longer.